<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34638992</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>19</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10649</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms221910649</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a disease with a resilient neuroinflammatory component caused by activated microglia and infiltrated immune cells. How to successfully balance neuroprotective versus neurotoxic actions through the use of anti-inflammatory agents is still under debate. There has been a boost of awareness regarding the role of extracellular ATP and purinergic receptors in modulating the physiological and pathological mechanisms in the nervous system. Particularly in ALS, it is known that the purinergic ionotropic P2X7 receptor plays a dual role in disease progression by acting at different cellular and molecular levels. In this context, we previously demonstrated that the P2X7 receptor antagonist, brilliant blue G, reduces neuroinflammation and ameliorates some of the pathological features of ALS in the SOD1-G93A mouse model. Here, we test the novel, noncommercially available, and centrally permeant Axxam proprietary P2X7 antagonist, AXX71, in SOD1-G93A mice, by assessing some behavioral and molecular parameters, among which are disease progression, survival, gliosis, and motor neuron wealth. We demonstrate that AXX71 affects the early symptomatic phase of the disease by reducing microglia-related proinflammatory markers and autophagy without affecting the anti-inflammatory markers or motor neuron survival. Our results suggest that P2X7 modulation can be further investigated as a therapeutic strategy in preclinical studies, and exploited in ALS clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Apolloni</LastName><ForeName>Savina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fondazione Santa Lucia Istituto di Ricovero e Cura a Carattere Scientifico, Preclinical Neuroscience, Via del Fosso di Fiorano 65, 00143 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabbrizio</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Fondazione Santa Lucia Istituto di Ricovero e Cura a Carattere Scientifico, Preclinical Neuroscience, Via del Fosso di Fiorano 65, 00143 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amadio</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9266-4597</Identifier><AffiliationInfo><Affiliation>Fondazione Santa Lucia Istituto di Ricovero e Cura a Carattere Scientifico, Preclinical Neuroscience, Via del Fosso di Fiorano 65, 00143 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Napoli</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Fondazione Santa Lucia Istituto di Ricovero e Cura a Carattere Scientifico, Preclinical Neuroscience, Via del Fosso di Fiorano 65, 00143 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freschi</LastName><ForeName>Mattia</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0800-5087</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sironi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pevarello</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Axxam SpA, Openzone, Via Meucci 3, Bresso, 20091 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarroni</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Axxam SpA, Openzone, Via Meucci 3, Bresso, 20091 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liberati</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Axxam SpA, Openzone, Via Meucci 3, Bresso, 20091 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendotti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1055-1271</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volont&#xe9;</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7362-8307</Identifier><AffiliationInfo><Affiliation>Fondazione Santa Lucia Istituto di Ricovero e Cura a Carattere Scientifico, Preclinical Neuroscience, Via del Fosso di Fiorano 65, 00143 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Research Council (CNR), Institute for Systems Analysis and Computer Science "A. Ruberti", Via Dei Taurini 19, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Path for ALS</GrantID><Agency>Agenzia di Ricerca per la Sclerosi Laterale Amiotrofica</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058920">Purinergic P2X Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058469">Receptors, Purinergic P2X</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053580" MajorTopicYN="N">Muscle Strength</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058920" MajorTopicYN="N">Purinergic P2X Receptor Antagonists</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058469" MajorTopicYN="N">Receptors, Purinergic P2X</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">NF-&#x3ba;B</Keyword><Keyword MajorTopicYN="N">NOX2</Keyword><Keyword MajorTopicYN="N">P2X7</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>13</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34638992</ArticleId><ArticleId IdType="pmc">PMC8508678</ArticleId><ArticleId IdType="doi">10.3390/ijms221910649</ArticleId><ArticleId IdType="pii">ijms221910649</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McCauley M.E., Baloh R.H. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715&#x2013;730. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff J.R., Simpson E.P., Appel S.H. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr. Opin. Neurol. 2018;31:635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C., D&#x2019;Ambrosi N. Membrane compartments and purinergic signalling: The purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J. 2009;276:318&#x2013;329. doi: 10.1111/j.1742-4658.2008.06793.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2008.06793.x</ArticleId><ArticleId IdType="pubmed">19076212</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. Advances in Experimental Medicine and Biology. Springer Nature; London, UK: 2020. Introduction to Purinergic Signalling in the Brain.</Citation><ArticleIdList><ArticleId IdType="pubmed">32034706</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. Purinergic Signalling: Therapeutic Developments. Front. Pharmacol. 2017;8:661. doi: 10.3389/fphar.2017.00661.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00661</ArticleId><ArticleId IdType="pmc">PMC5622197</ArticleId><ArticleId IdType="pubmed">28993732</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G. The therapeutic potential of purinergic signalling. Biochem. Pharmacol. 2018;151:157&#x2013;165. doi: 10.1016/j.bcp.2017.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2017.07.016</ArticleId><ArticleId IdType="pubmed">28735873</ArticleId></ArticleIdList></Reference><Reference><Citation>Illes P., Burnstock G., Tang Y. Astroglia-Derived ATP Modulates CNS Neuronal Circuits. Trends Neurosci. 2019;42:885&#x2013;898. doi: 10.1016/j.tins.2019.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2019.09.006</ArticleId><ArticleId IdType="pubmed">31704181</ArticleId></ArticleIdList></Reference><Reference><Citation>Khakh B.S., North R.A. Neuromodulation by Extracellular ATP and P2X Receptors in the CNS. Neuron. 2012;76:51&#x2013;69. doi: 10.1016/j.neuron.2012.09.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.09.024</ArticleId><ArticleId IdType="pmc">PMC4064466</ArticleId><ArticleId IdType="pubmed">23040806</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C., Amadio S., Cavaliere F., D&#x2019;Ambrosi N., Vacca F., Bernardi G. Extracellular ATP and neurodegeneration. Curr. Drug Target CNS Neurol. Disord. 2003;2:403&#x2013;412. doi: 10.2174/1568007033482643.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568007033482643</ArticleId><ArticleId IdType="pubmed">14683468</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C., Apolloni S., Parisi C., Amadio S. Purinergic contribution to amyotrophic lateral sclerosis. Neuropharmacology. 2016;104:180&#x2013;193. doi: 10.1016/j.neuropharm.2015.10.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.10.026</ArticleId><ArticleId IdType="pubmed">26514402</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C., Apolloni S., Carr&#xec; M.T., D&#x2019;Ambrosi N. ALS: Focus on purinergic signalling. Pharmacol. Ther. 2011;132:111&#x2013;122. doi: 10.1016/j.pharmthera.2011.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2011.06.002</ArticleId><ArticleId IdType="pubmed">21704075</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C., Amadio S., Liguori F., Fabbrizio P. Duality of P2X7 Receptor in Amyotrophic Lateral Sclerosis. Front. Pharmacol. 2020;11:1148. doi: 10.3389/fphar.2020.01148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01148</ArticleId><ArticleId IdType="pmc">PMC7394054</ArticleId><ArticleId IdType="pubmed">32792962</ArticleId></ArticleIdList></Reference><Reference><Citation>Cie&#x15b;lak M., Roszek K., Wujak M. Purinergic implication in amyotrophic lateral sclerosis&#x2014;from pathological mechanisms to therapeutic perspectives. Purinergic Signal. 2019;15:1&#x2013;15. doi: 10.1007/s11302-018-9633-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-018-9633-4</ArticleId><ArticleId IdType="pmc">PMC6439052</ArticleId><ArticleId IdType="pubmed">30430356</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G., Knight G.E. The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal. 2018;14:1&#x2013;18. doi: 10.1007/s11302-017-9593-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-017-9593-0</ArticleId><ArticleId IdType="pmc">PMC5842154</ArticleId><ArticleId IdType="pubmed">29164451</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevarello P., Bovolenta S., Tarroni P., Za L., Severi E., Torino D., Vitalone R. P2X7 antagonists for CNS indications: Recent patent disclosures. Pharm. Pat. Anal. 2017;6:61&#x2013;76. doi: 10.4155/ppa-2016-0044.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/ppa-2016-0044</ArticleId><ArticleId IdType="pubmed">28248151</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C., Apolloni S., Skaper S.D., Burnstock G. P2X7 Receptors: Channels, Pores and More. CNS Neurol. Disord. Drug Targets. 2012;11:705&#x2013;721. doi: 10.2174/187152712803581137.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152712803581137</ArticleId><ArticleId IdType="pubmed">22963440</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori F., Amadio S., Volont&#xe9; C. Where and Why Modeling Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci. 2021;22:3977. doi: 10.3390/ijms22083977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22083977</ArticleId><ArticleId IdType="pmc">PMC8070525</ArticleId><ArticleId IdType="pubmed">33921446</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Amadio S., Montilli C., Volont&#xe9; C., D&#x2019;Ambrosi N. Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:4102&#x2013;4116. doi: 10.1093/hmg/ddt259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt259</ArticleId><ArticleId IdType="pubmed">23736299</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrizio P., Apolloni S., Bianchi A., Salvatori I., Valle C., Lanzuolo C., Bendotti C., Nardo G., Volont&#xe9; C. P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Brain Pathol. 2019;30:272&#x2013;282. doi: 10.1111/bpa.12774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12774</ArticleId><ArticleId IdType="pmc">PMC7065186</ArticleId><ArticleId IdType="pubmed">31376190</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Parisi C., Pesaresi M.G., Rossi S., Carri M.T., Cozzolino M., Volont&#xe9; C., D&#x2019;Ambrosi N. The NADPH Oxidase Pathway Is Dysregulated by the P2X7 Receptor in the SOD1-G93A Microglia Model of Amyotrophic Lateral Sclerosis. J. Immunol. 2013;190:5187&#x2013;5195. doi: 10.4049/jimmunol.1203262.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1203262</ArticleId><ArticleId IdType="pubmed">23589615</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ambrosi N., Finocchi P., Apolloni S., Cozzolino M., Ferri A., Padovano V., Pietrini G., Carr&#xec; M.T., Volont&#xe9; C. The Proinflammatory Action of Microglial P2 Receptors Is Enhanced in SOD1 Models for Amyotrophic Lateral Sclerosis. J. Immunol. 2009;183:4648&#x2013;4656. doi: 10.4049/jimmunol.0901212.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901212</ArticleId><ArticleId IdType="pubmed">19734218</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C., Napoli G., Amadio S., Spalloni A., Apolloni S., Longone P., Volont&#xe9; C. MicroRNA-125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ. 2016;23:531&#x2013;541. doi: 10.1038/cdd.2015.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2015.153</ArticleId><ArticleId IdType="pmc">PMC5072447</ArticleId><ArticleId IdType="pubmed">26794445</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C., Arisi I., D&#x2019;Ambrosi N., Storti A.E., Brandi R., D&#x2019;Onofrio M., Volont&#xe9; C. Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis. 2013;4:e959. doi: 10.1038/cddis.2013.491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.491</ArticleId><ArticleId IdType="pmc">PMC3877562</ArticleId><ArticleId IdType="pubmed">24336079</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C., Apolloni S., Parisi C. MicroRNAs: Newcomers into the ALS Picture. CNS Neurol. Disord. Drug Targets. 2015;14:194&#x2013;207. doi: 10.2174/1871527314666150116125506.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527314666150116125506</ArticleId><ArticleId IdType="pubmed">25613506</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman M., Peluffo H., Beckman J.S., Cassina P., Barbeito L. Extracellular ATP and the P2X7receptor in astrocyte-mediated motor neuron death: Implications for amyotrophic lateral sclerosis. J. Neuroinflam. 2010;7:33. doi: 10.1186/1742-2094-7-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-33</ArticleId><ArticleId IdType="pmc">PMC2901222</ArticleId><ArticleId IdType="pubmed">20534165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman M., Levy M., Cassina P., Barbeito L., Beckman J.S. P2X7 receptor-induced death of motor neurons by a peroxynitrite/FAS-dependent pathway. J. Neurochem. 2013;126:382&#x2013;388. doi: 10.1111/jnc.12286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12286</ArticleId><ArticleId IdType="pmc">PMC3716845</ArticleId><ArticleId IdType="pubmed">23646980</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett R., Sluyter V., Watson D., Sluyter R., Yerbury J.J. P2X7 antagonism using brilliant blue G reduces body weight loss and prolongs survival in female SOD1G93A amyotrophic lateral sclerosis mice. PeerJ. 2017;5:e3064. doi: 10.7717/peerj.3064.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.3064</ArticleId><ArticleId IdType="pmc">PMC5335685</ArticleId><ArticleId IdType="pubmed">28265522</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Amadio S., Parisi C., Matteucci A., Potenza R.L., Armida M., Popoli P., D&#x2019;Ambrosi N., Volont&#xe9; C. Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis. Dis. Model. Mech. 2014;7:1101&#x2013;1109. doi: 10.1242/dmm.017038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.017038</ArticleId><ArticleId IdType="pmc">PMC4142730</ArticleId><ArticleId IdType="pubmed">25038061</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervetto C., Frattaroli D., Maura G., Marcoli M. Motor neuron dysfunction in a mouse model of ALS: Gender-dependent effect of P2X7 antagonism. Toxicology. 2013;311:69&#x2013;77. doi: 10.1016/j.tox.2013.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2013.04.004</ArticleId><ArticleId IdType="pubmed">23583883</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrizio P., Amadio S., Apolloni S., Volont&#xe9; C. P2X7 receptor activation modulates autophagy in SOD1-g93a mouse microglia. Front. Cell. Neurosci. 2017;11:249. doi: 10.3389/fncel.2017.00249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00249</ArticleId><ArticleId IdType="pmc">PMC5566572</ArticleId><ArticleId IdType="pubmed">28871219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly D., Dongol A., Cuthbertson P., Guy T.V., Geraghty N.J., Sophocleous R.A., Sin L., Turner B.J., Watson D., Yerbury J.J., et al. The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice. Purinergic Signal. 2020;16:109&#x2013;122. doi: 10.1007/s11302-020-09692-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-020-09692-4</ArticleId><ArticleId IdType="pmc">PMC7166237</ArticleId><ArticleId IdType="pubmed">32170537</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenouchi T., Sekiyama K., Tsukimoto M., Iwamaru Y., Fujita M., Sugama S., Kitani H., Hashimoto M. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging. Academic Press; Cambridge, MA, USA: 2015. Role of Autophagy in P2X7 Receptor-Mediated Maturation and Unconventional Secretion of IL-1&#x3b2; in Microglia.</Citation></Reference><Reference><Citation>Plaza-Zabala A., Sierra-Torre V., Sierra A. Autophagy and microglia: Novel partners in neurodegeneration and aging. Int. J. Mol. Sci. 2017;18:598. doi: 10.3390/ijms18030598.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18030598</ArticleId><ArticleId IdType="pmc">PMC5372614</ArticleId><ArticleId IdType="pubmed">28282924</ArticleId></ArticleIdList></Reference><Reference><Citation>Porras M.A.G., Sieck G.C., Mantilla C.B. Impaired autophagy in motor neurons: A final common mechanism of injury and death. Physiology. 2018;33:211&#x2013;224. doi: 10.1152/physiol.00008.2018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiol.00008.2018</ArticleId><ArticleId IdType="pmc">PMC5966659</ArticleId><ArticleId IdType="pubmed">29638184</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiangou Y., Facer P., Durrenberger P., Chessell I.P., Naylor A., Bountra C., Banati R.R., Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12. doi: 10.1186/1471-2377-6-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-6-12</ArticleId><ArticleId IdType="pmc">PMC1413551</ArticleId><ArticleId IdType="pubmed">16512913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Li L., Chen S., Yang D., Wang Y., Zhang X., Wang Z., Le W. Rapamycin treatment augments motor neuron degeneration in SOD1G93Amouse model of amyotrophic lateral sclerosis. Autophagy. 2011;7:412&#x2013;425. doi: 10.4161/auto.7.4.14541.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.7.4.14541</ArticleId><ArticleId IdType="pubmed">21193837</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizushima N., Yoshimori T., Levine B. Methods in Mammalian Autophagy Research. Cell. 2010;140:313&#x2013;326. doi: 10.1016/j.cell.2010.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.028</ArticleId><ArticleId IdType="pmc">PMC2852113</ArticleId><ArticleId IdType="pubmed">20144757</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K. Familial versus sporadic amyotrophic lateral sclerosis&#x2014;A false dichotomy? Brain. 2011;134:3429&#x2013;3431. doi: 10.1093/brain/awr296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr296</ArticleId><ArticleId IdType="pubmed">22051609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Ruiz C., Calzaferri F., Garc&#xed;a A.G. P2x7 receptor antagonism as a potential therapy in amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2020;13:93. doi: 10.3389/fnmol.2020.00093.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00093</ArticleId><ArticleId IdType="pmc">PMC7303288</ArticleId><ArticleId IdType="pubmed">32595451</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Ruiz C., Garc&#x131;&#xe1;-Magro N., Negredo P., Avendan&#xf5; C., Bhattacharya A., Ceusters M., Garc&#x131;&#xe1; A.G. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1G93A female mice. Dis. Model. Mech. 2020;13 doi: 10.1242/dmm.045732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.045732</ArticleId><ArticleId IdType="pmc">PMC7648608</ArticleId><ArticleId IdType="pubmed">33174532</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Fabbrizio P., Amadio S., Volont&#xe9; C. Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression. J. Neuroinflam. 2016;13:191. doi: 10.1186/s12974-016-0658-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0658-8</ArticleId><ArticleId IdType="pmc">PMC4994328</ArticleId><ArticleId IdType="pubmed">27549088</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Fabbrizio P., Parisi C., Amadio S., Volont&#xe9; C. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1G93AMouse Model of Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2016;53:518&#x2013;531. doi: 10.1007/s12035-014-9019-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-9019-8</ArticleId><ArticleId IdType="pubmed">25482048</ArticleId></ArticleIdList></Reference><Reference><Citation>Takenouchi T., Fujita M., Sugama S., Kitani H., Hashimoto M. The role of the P2X7 receptor signaling pathway for the release of autolysosomes in microglial cells. Autophagy. 2009;5:723&#x2013;724. doi: 10.4161/auto.5.5.8478.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.5.5.8478</ArticleId><ArticleId IdType="pubmed">19337025</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas D., Qureshi O.S., Lee W.Y., Croudace J.E., Mura M., Lammas D.A. ATP-induced autophagy is associated with rapid killing of intracellular mycobacteria within human monocytes/macrophages. BMC Immunol. 2008;9:35. doi: 10.1186/1471-2172-9-35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2172-9-35</ArticleId><ArticleId IdType="pmc">PMC2483257</ArticleId><ArticleId IdType="pubmed">18627610</ArticleId></ArticleIdList></Reference><Reference><Citation>Young C.N.J., Sinadinos A., Lefebvre A., Chan P., Arkle S., Vaudry D., Gorecki D.C. A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90. Autophagy. 2015;11:113&#x2013;130. doi: 10.4161/15548627.2014.994402.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/15548627.2014.994402</ArticleId><ArticleId IdType="pmc">PMC4502824</ArticleId><ArticleId IdType="pubmed">25700737</ArticleId></ArticleIdList></Reference><Reference><Citation>Illes P., M&#xfc;ller C.E., Jacobson K.A., Grutter T., Nicke A., Fountain S.J., Kennedy C., Schmalzing G., Jarvis M.F., Stojilkovic S.S., et al. Update of P2X receptor properties and their pharmacology: IUPHAR Review 30. Br. J. Pharmacol. 2020;178:489&#x2013;514. doi: 10.1111/bph.15299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15299</ArticleId><ArticleId IdType="pmc">PMC8199792</ArticleId><ArticleId IdType="pubmed">33125712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya A., Wang Q., Ao H., Shoblock J.R., Lord B., Aluisio L., Fraser I., Nepomuceno D., Neff R.A., Welty N., et al. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br. J. Pharmacol. 2013;178:489&#x2013;514. doi: 10.1111/bph.12314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12314</ArticleId><ArticleId IdType="pmc">PMC3792000</ArticleId><ArticleId IdType="pubmed">23889535</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzasegola C., Caron I., Daleno C., Ronchi A., Minoia C., Carr&#xec; M.T., Bendotti C. Treatment with lithium carbonate does not improve disease progression in two different strains of SOD1 mutant mice. Amyotroph. Lateral Scler. 2009;10:221&#x2013;228. doi: 10.1080/17482960902803440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960902803440</ArticleId><ArticleId IdType="pubmed">19308767</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluyter R., Bartlett R., Ly D., Yerbury J. P2X7 receptor antagonism in amyotrophic lateral sclerosis. Neural Regen. Res. 2017;12:749&#x2013;750. doi: 10.4103/1673-5374.206643.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.206643</ArticleId><ArticleId IdType="pmc">PMC5461610</ArticleId><ArticleId IdType="pubmed">28616029</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>